Drug Profile
Research programme: aurora kinase inhibitors - Chroma Therapeutics
Alternative Names: CCT-129202; Multi-kinase inhibitors - Chroma TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Chroma Therapeutics
- Class Small molecules
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 15 May 2008 Preclinical development is ongoing
- 09 Mar 2005 Preclinical trials in Cancer in United Kingdom (unspecified route)